As the number of new molecular entities coming out of discovery exhibit developability challenges, developers are looking for ways to predict and overcome potential issues. During preclinical research, important distinctive tools are those capable of improving early phase decisions. These include selecting the best form among several promising candidates, solid state chemistry, human drug metabolism and pharmacokinetic (DMPK) predictability, and formulation technology to enhance bioavailability. Catalent’s highly experienced and specialized drug development teams enlist an integrated suite of tools to take the guess work out of evaluating risks and help you make informed data-driven decisions as candidate’s transition from discovery to development.
Catalent bridges the gap between discovery and development to reduce risks and determine potential obstacles before making big investments in later development stages.